Актуальная цена акций Compugen (CGEN) на сегодня на фондовом рынке. Здесь можно купить и продать ценные бумаги Compugen онлайн. The current consensus among 2 polled investment analysts is to Buy stock in Compugen Ltd. This rating has held steady since January, when it was unchanged from a Buy rating. Is Compugen (CGEN) Outperforming Other Medical Stocks This Year? Стоимость акции Compugen Ltd. сегодня, графики динамики котировок, рекомендации. Compugen CGEN. Доходность за полгода. −30,91%. Сектор. Здравоохранение. Логотип акции Compugen, CGEN. Обзор. Пульс.
Новости по акциям компании Compugen Ltd.
Найдите последние курсы акций Compugen Ltd (CGEN), историю, новости и другую важную информацию, которая поможет вам в торговле акциями и инвестировании. Compugen Ltd NASDAQ: CGEN is a therapeutic company focused on infrastructure to discover drug targets and develop therapeutics. У Compugen два препарата-кандидата (COM701 и COM902) для лечения опухолей. На тогах 29 декабря акция CGEN стоила $0,68. Рыночная капитализация составила $59,41 млн. Анализируйте акции Compugen (CGEN). График котировок, курс акций на сегодня, дивиденды, аналитика, последние новости и стоимость акций.
Member Sign In
Compugen Ltd. stock price monthly change. +19.09%. The current consensus among 2 polled investment analysts is to Buy stock in Compugen Ltd. This rating has held steady since January, when it was unchanged from a Buy rating. Все новости о компании Compugen Ltd. на русском языке с анализом и ссылкой на оригинальный источник.
Новости по акциям компании Compugen Ltd.
Subscribers to Market Wire News service may receive up to 500 per month. An unsubscribe message will be sent to your number confirming the cancellation, but no more messages will be sent after that one. Optionally, you may email support marketwirenews.
Цифровые знаки токены далее — токены не являются законным платежным средством и не обязательны к приему в качестве средства платежа. Токены не обеспечиваются государством. Приобретение токенов может привести к полной потере денежных средств и иных объектов гражданских прав инвестиций , переданных в обмен на токены в том числе в результате волатильности стоимости токенов; технических сбоев ошибок ; совершения противоправных действий, включая хищение.
Всё сказанное в данном видео является исключительно мнением спикера.
Данное видео не рекомендуется к просмотру лицам, не достигшим 18 лет. Falling Ft.
In terms of future funding, non-dilutive funding of our pipeline assets is our priority. On this front, it is worth noting that the trend in immunotherapy is to combine and treat earlier, and we believe the profile of our lead assets COM701 and COM902 make them ideal combination candidates to be used in earlier treatment settings. Additionally, there is increasing excitement around the potential of IL-18 pathway modulation in immunooncology.
Finally, through our partnership with AstraZeneca, we may become eligible for future milestone payments. And with that, I will hand over to Alberto for the financial update. Alberto Sessa: Thank you, Anat. I will start with our cash balance. The company has no debt.
We recognize the importance of cash efficiency, and we are disciplined in how we deploy our cash resources, ensuring we will focus on reaching key milestones with our available cash runway through at least the end of 2024. Expenses for the second quarter of 2023 were in line with our plans. With that, I will hand back to Anat to summarize. Anat Cohen-Dayag: Thank you, Alberto. To summarize, we continue to execute and deliver on our goals.
Compugen News
A Company Information Compugen Ltd. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates.
Речь идет о перераспределении налога с этой прибыли, и только. Далее каждый брокер самостоятельно определит порядок распределения полученных средств среди своих клиентов.
Частичной разблокировки удалось добиться после переговоров с рядом дружественных контрагентов. Объём этой валюты составил 1,44 млрд рублей по курсу конвертации вышестоящим контрагентом на 31 января 2024 года. Общая сумма заблокированных после санкций США активов составила немногим более 3 млрд. Для восстановления доступа инвесторов к заблокированным активам БКС получает всю необходимую информацию от биржи и СПБ Банка, а также выполняет все их инструкции.
Learn More about companies similar to Compugen. The official website for Compugen is www. Learn More about contacing Compugen investor relations. All rights reserved. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.
The high in the last 52 weeks of Compugen stock was 2. According to the current price, Compugen is 90. What are analysts forecasts for Compugen stock? The 10 analysts offering price forecasts for Compugen have a median target of 6.
The median estimate represents a 35.
Динамика изменения стоимости активов
- Sponsor Center
- Compugen, акция обыкновенная (IL0010852080, CGEN, CW9, CGEN.P)
- Sponsor Center
- Compugen pipeline
- Акции Compugen выросли на 14% благодаря инвестициям в размере $20 млн
- Compugen - Биржевая Цена
CGEN News and Press Compugen Ltd.
Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer. Visit Performance Disclosure for information about the performance numbers displayed above. Visit www.
Subscribers to Market Wire News service may receive up to 500 per month. An unsubscribe message will be sent to your number confirming the cancellation, but no more messages will be sent after that one.
Optionally, you may email support marketwirenews.
Looking at the totality of the data we have presented to date in how to treat cancer patients, there was enthusiasm among those we spoke with regarding responses demonstrated with our triple combination approach in patients with microsatellite stable endometrial cancer, who had failed standard of care, including prior pembro and lenvatinib treatment. For these patients, there were no other treatment options.
The responses were durable and supported by immune activation better than what one would expect for an anti-PD-1 alone. This endometrial data is consistent with the antitumor activity we reported for COM701 based combinations in patients with other hard to treat tumors, including microsatellite stable colorectal cancer, platinum resistant ovarian cancer and checkpoint inhibitor experienced non-small cell lung cancer patients. Reflecting on the totality of the data to date, in patients typically not responsive to standard of care, including immunotherapy, our data suggests that our COM701 based combinations have the potential to offer a treatment option with a favorable safety profile for how to treat patients across the spectrum of PD-L1 expression levels, in patients who are anti-PD-1 treatment refractory, pointing to a potential COM701 mediated mechanism of action.
Our immediate focus is on expanding our data in 2 indications, platinum resistant ovarian cancer and MSS colorectal cancer, while continuing to invest in biomarker discovery, which is important in efficiently setting our development path forward. Blocking TIGIT resulted in a 4-time greater overall response rate and a doubling the progression-free survival on top of standard of care and Roche has initiated a Phase 3 trial in first line hepatocellular cancer based on these results. We were pleased that the discussant of Roche presentations highlighted the potential significance of adding PVRIG blockade in hepatocellular cancer.
This is another hard to treat indication which may serve as a fit for COM701 treatment. Our discovery of PVRIG and the extensive research, we have conducted to test the effect of unlocking its biological function as a new drug target in the context of the DNAM axis support the need to block it. This belief is consistently being reinforced as we rollout our clinical data across multiple indications.
The data available today suggests that Fc design of the TIGIT antibody may either not matter or it may be better to have a reduced or inactive Fc domain as we have. Along with a very successful ASCO, I would like to refer to additional progress we have made in the first half of the year.
Member Sign In
Какова была прибыль Compugen на акцию за последние 12 месяцев TTM? Compugen Прибыль на акцию за 12 месяцев составляет -0. К какому сектору относится компания Compugen? Компания Compugen относится к сектору Здравоохранение.
Кроме того, терапевтический портфель иммуноонкологических программ Компании на ранних стадиях состоит из программ, направленных на устранение различных механизмов иммунной резистентности, включая миелоидные мишени. Контактное лицо компании: Ивонн Нотон, доктор философии, руководитель отдела по связям с инвесторами и корпоративным коммуникациям Электронная почта: [email protected] Тел.
Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer. Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www. Real time prices by BATS.
Компания имеет соглашение о сотрудничестве с Bayer Pharma AG для исследований, разработки и коммерциализации антител на основе терапии против регуляторов иммунных контрольных точек компании; Bristol-Myers Squibb для оценки безопасности и переносимости COM701 в сочетании с ингибитором иммунных контрольных точек PD-1 Bristol-Myers Squibb Opdivo у пациентов с прогрессирующими солидными опухолями; и Медицинской школой Джона Хопкинса для оценки новых Т-клеточных и миелоидных контрольных точек. Компания имеет лицензионное соглашение с AstraZeneca на разработку биспецифических и мультиспецифических иммуноонкологических антител. По состоянию на конец торгового дня 2024-02-16, котировка акций цена 1 акции Compugen Ltd составляет 2.
Данные о показателе Free Float компании Compugen Ltd не найдены.
Доходы Compugen Ltd.
Compugen Trading Down 2.1 %. CGEN opened at $0.80 on Tuesday. The stock has a market cap of $69.01 million, a price-to-earnings ratio of -1.99 and a beta of 2.70. Operator: Ladies and gentlemen, thank you for joining us today. Welcome to Compugen’s Second Quarter 2023 Results Conference Call. At this time, all participants are in a listen-only mode. Compugen Ltd.-израильская компания, занимающаяся терапевтическими открытиями и разработками. Зарегистрирована в 1993 г. в Израиле. График и курс акций компании Compugen Ltd: котировки, аналитика и прогнозы. Get the latest news and real-time alerts from Compugen Ltd. (CGEN) stock at Seeking Alpha. Where is Compugen stock heading? Wall Street analysts weigh in with their latest ratings and CGEN price targets at